Skip to content

Desferal in COVID-19

Evaluation of the effects of Desferal on clinical symptoms in patients with COVID-19

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200506047323N4
Enrollment
60
Registered
2020-08-01
Start date
2020-08-10
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, virus identified. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: The standard treatment regimen for COVID-19 along with a 10 cc (500 mg) of Deferoxamine solution (Deferoxir, Exirdaru Company, Iran) divided in four times a day thr

Sponsors

Bandare-abbas University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age >18 years Positive polymerase chain reaction (PCR) test for COVID-19 Primary clinical symptoms Hospitalized and moderate patients Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm

Exclusion criteria

Exclusion criteria: Underlying diseases, including renal failure (serum creatinine >2), myocarditis and arrhythmia, anemia (hemoglobin<4-8), lower respiratory tract infection, and asthma Patients requiring intubation or frequent use of respiratory drugs Severe and critical patients History of allergy to studied drug Pregnancy and breastfeeding

Design outcomes

Primary

MeasureTime frame
Viral load. Timepoint: Before intervention and 7 days after the start of the intervention. Method of measurement: Polymerase chain reaction (PCR) test.;Body temperature. Timepoint: Before intervention and daily during the study. Method of measurement: Thermometer.;Oxygen saturation. Timepoint: Before intervention and daily during the study. Method of measurement: Pulse oximeter.

Secondary

MeasureTime frame
Duration of hospitalization. Timepoint: Time period from admission to discharge. Method of measurement: Patient's file.;C-reactive protein. Timepoint: Before intervention and 7 days after the start of the intervention. Method of measurement: C-RP kit.;Incidence of serious adverse events. Timepoint: Before intervention and daily during the study. Method of measurement: Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Fathalipour

Bandare-abbas University of Medical Sciences

m.fathalipour@hums.ac.ir+98 76 3371 0406

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026